Nectar lifesciences Ltd. has announced a significant update regarding the divestiture of its Empty Hard Gelatin Capsule business division. The pharmaceutical company has extended the completion timeline for the slump sale transaction, setting a new target date of July 31, 2026.

Transaction Details

The company made this disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory framework mandates listed companies to inform stock exchanges and investors about material events and corporate developments that could impact share prices or investor decisions.

Corporate Communication

The announcement was formally communicated to both major Indian stock exchanges where the company's shares are listed. The disclosure ensures transparency and keeps stakeholders informed about the progress of this strategic business divestiture.

Company Background

Nectar Lifesciences operates from its corporate office located at Plot No. 110, Industrial Area, Phase 1, Chandigarh, with its registered office and manufacturing works situated in Dera Bassi, Punjab. The company maintains its corporate identity under CIN: L21000PB1995PLC016664, reflecting its incorporation in Punjab in 1995.

This timeline extension provides the company with additional time to complete all necessary formalities and ensure a smooth transition of the Empty Hard Gelatin Capsule business operations to the acquiring entity.

Nectar lifesciences Limited has announced the launch of its second 100-day special outreach initiative titled 'Saksham Niveshak' from April 01, 2026, to July 09, 2026. The campaign has been initiated pursuant to communication from the Investor Education and Protection Fund Authority, Ministry of Corporate Affairs, dated March 27, 2026.

Campaign Objectives and Benefits

The Saksham Niveshak campaign serves dual purposes for shareholders, focusing on critical administrative updates and financial recoveries. The initiative aims to assist investors in updating their KYC details, including bank account mandates, nominee registration, and contact information such as email addresses, mobile numbers, and postal addresses. Additionally, the campaign enables shareholders to claim their unpaid or unclaimed dividends, specifically targeting Final Dividend 2018-19 and 2019-20.

Shareholder Action Requirements

The company emphasizes the importance of maintaining updated records with the Registrar and Share Transfer Agent or Depository Participants. Since dividends are payable only through electronic mode, amounts will be credited to shareholders' bank accounts only after required information and documents are properly updated. Key details that require updating include:

• PAN details
• Nomination information
• Contact information including postal address and mobile number
• Bank account details
• Specimen signature

Contact Information and Support

Shareholders seeking to participate in the campaign can reach out through multiple channels. The company has provided comprehensive contact details for both its Registrar and Share Transfer Agent, as well as direct company contacts.

Regulatory Compliance and Urgency

The campaign carries significant regulatory implications for shareholders. According to applicable provisions, dividends that remain unclaimed or unpaid for seven consecutive years, along with corresponding shares, are liable to be transferred to the IEPF Authority. The company has made unclaimed dividend details for Final Dividend 2018-19 and 2019-20 available on its website at www.neclife.com/about-3-12 .

Shareholders with incomplete KYC records are advised to approach their Depository Participant for shares held in electronic mode, or contact the RTA or company directly for shares held in physical mode. The company urges all investors to take prompt action during the campaign period to safeguard their entitlements and avoid the complexities of claiming dividends and shares from the IEPF Authority.